Recovery & repair
BPC-157
People use BPC-157 to help tendons, ligaments, muscles, and the gut heal; almost all of the research is in animals.
One-time step
Research use only
Scroll through the five parts below. The tick box and button are at the end. Your BPC-157 dose then opens right here. Once only, here and on the Lifebuff site.
Quick guide
Your dose
500 mcg
5units
Draw to the 5 line on a 0.5 mL U-100 insulin syringe.
Range 250–500 mcg · 2.5–5 units
Mixed for you
Your 20 mg vial comes mixed with 2 mL bacteriostatic water. Each unit is 100 mcg.
-
How often
Twice a day
Every day (7 days a week)
-
When
Morning and evening
-
Where
Belly, thigh, or near the injury
Under the skin
-
Storage
In the fridge (2-8 °C / 36-46 °F)
-
Cycle
6 weeks on · 2 weeks off
Full course: 3 vials
- Evidence
- Mostly animal studies; three small human studies, none with a comparison group
Week by weekWhat to expect
- Week 1-2: No human data; some report early gains, others nothing yet
- Week 2-4: Some report easier stairs, grip, or training
- Week 4-8: Course ends after week 6; weeks 7-8 are your break
- Week 8-12: Recheck; repeat if needed, see a doctor if no change
- Side effects: 911: hives or trouble breathing; fever: see a doctor; see Side effects
More on each stage
- Week 1-2
- No human study has measured this. Many users report first improvements within 1-2 weeks; others feel nothing yet.
- Week 2-4
- People who respond often report clearer progress by weeks 3-4: easier stairs, grip, or training. Results vary from person to person and injury to injury.
- Week 4-8
- The store course ends after week 6; weeks 7-8 are your break. No human study has tracked under-the-skin use this long. Community courses usually run 4 to 8 weeks.
- Week 8-12
- Judge the injury after the break. If it still needs help, start a second 6-week round. If nothing changed after a full round, see a doctor about the injury before trying again.
Based on what people report in the community sources below. Results vary, and many responses are anecdotal.
Why people use itBenefits and research
-
Tendon and ligament healing
Animal/lab studyRats with a cut Achilles tendon or knee ligament healed stronger and regained function better when given daily BPC-157 injections.810
-
Muscle repair
Animal/lab studyRats with a fully cut thigh muscle regained more strength and function over 72 days on daily BPC-157.9
-
Gut lining protection
Animal/lab studyIn rats, BPC-157 protected the stomach and gut lining from damage caused by alcohol and anti-inflammatory painkillers (NSAIDs such as ibuprofen).14
-
Skin wound healing
Animal/lab studyCuts, burns, and diabetic wounds healed faster in rats and mice given BPC-157.15
-
Knee pain relief
Human studyIn a small clinic review, 11 of 12 people reported less knee pain after one 4 mg BPC-157 injection into the knee by a doctor.4
-
Faster injury recovery
Community reportMost users who post about it report improvement within 1-2 weeks and clear progress by weeks 3-4.18
What it has been studied for
- Knee pain from several causes (one shot into the knee joint; 16 people, 12 given BPC-157 alone)4Human study
- Interstitial cystitis, a painful bladder condition (injected into the bladder during one procedure, 12 women)5Human study
- Safety of an IV drip of up to 20 mg (2 adults; no side effects or blood-test changes)6Human study
- Tendon, ligament, muscle, and bone injuries (35 of 36 studies in a 2025 review were in animals or cells)2810Animal/lab study
- Stomach ulcers, gut inflammation, and painkiller damage to the gut14Animal/lab study
- Skin wounds and burns15Animal/lab study
In the bodyHow it works
BPC-157 is a lab-made chain of 15 building blocks (amino acids). It copies part of a protein found in human stomach juice. In animal and lab studies, it seems to speed up healing in three ways. It grows new tiny blood vessels into hurt tissue, like building new roads to bring in supplies. It helps repair cells move into the injury, and it calms inflammation, the body's alarm system. Nobody has studied how it works in people.
In rat tendon cells, it helped repair cells survive stress and reach the injury. It also added docking spots for growth hormone, so the body's own growth hormone works harder there (lab study).
Turned up a switch that tells the body to grow new blood vessels. In rats with a blocked leg artery, blood flow came back faster (animal/lab study).
Helped cut thigh muscles in rats join back together and work again (animal study).
Protected the lining of the stomach and gut from damage by alcohol and painkillers in rats (animal study).
Helped cuts and burns heal faster in rats and mice (animal study).
Helped bone injuries heal better in animal studies (animal study).
Peak, half-life, clearancePharmacokinetics
- Peak
- Not established in humans. In rats and dogs given a shot into muscle, blood levels peaked within about 3 to 9 minutes.
- Half-life
- Not established in humans. In rats and dogs, half of the intact peptide was gone in under 30 minutes.
- Cleared
- Not established in humans. In rats, intact BPC-157 could no longer be detected 4 hours after a dose. It breaks down into small pieces and finally the amino acid proline, which the body reuses; the leftovers leave mainly through urine and bile.
Half-life is how long it takes the body to remove half of a dose.12
Research and communityDosing guidance
Lower
250 mcg
2.5 units
Typical
500 mcg
5 units
Twice a day. Morning and evening. Every day (7 days a week). Units are for a 20 mg vial mixed with 2 mL water (10 mg per mL).
What the community uses
Community reportLower end · maintenance / general recovery
100-200 mcg once daily
A community 'maintenance' dose some self-experimenters report for general recovery; it sits near the rat-derived human-equivalent estimate.1820
Most common · standard healing protocol
250-500 mcg once or twice daily
The standard healing protocol biohackers swap in most often for tendon, ligament, and muscle injuries, usually injected close to the injury.1820
Standard healing protocol (not tested in trials)
250-500 mcg under the skin, once or twice a day, for 4-8 weeks.18
Aggressive recovery for worse injuries (matches the store protocol)
500 mcg under the skin, twice a day, for 4-6 weeks.18
Low-dose maintenance
100-200 mcg under the skin once a day, 4 weeks on and 2 weeks off.18
Research protocols
Rat injury studies (tendon, ligament, muscle)
10 mcg per kg of body weight (also 10 ng per kg), injected into the belly cavity once a day, starting 30 minutes after the injury.8109
Converting the rat dose to a person (math estimate, not a tested human dose)
The FDA body-surface method divides a rat dose by 6.2. That turns 10 mcg per kg into about 1.6 mcg per kg, or roughly 100-115 mcg for a 60-70 kg adult. Community low doses of 100-200 mcg sit near this estimate.168
Human knee study (doctor-given)
A single 4 mg injection (2 mL of a 2,000 mcg per mL solution) into the knee joint. Two people needed a repeat after re-injury.4
Human bladder study (doctor-given)
10 mg total, injected around the inflamed area of the bladder during one scope procedure.5
Human IV safety pilot (doctor-given)
10 mg on day 1 and 20 mg on day 2, each mixed in 250 mL of saline and dripped into a vein over one hour.6
Practitioner guide (community-based)
200-500 mcg a day is the most common range; acute injuries twice a day, chronic problems 200-300 mcg once a day. Cycles of 8-12 weeks on and 4-8 weeks off.20
BPC-157 is not FDA-approved and is WADA-banned for sport. Community doses are extrapolated from rat data, not validated in human trials. The FDA flags immunogenicity and limited safety data, and long-term human safety is unknown.
Dosing guidance built from the cited research and community reports. It is not a prescription.
On and offCycling
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
On: 6 weeks Break: 2 weeks
A full course at the store pace takes 3 vials. A mixed vial keeps for up to 90 days.
Why the break helps
No study has tested whether breaks help with BPC-157. The break is a community habit with two practical reasons: it lets you see whether the injury holds up without the peptide, and it limits nonstop use of a compound with no long-term human safety data. Community runs are usually 4 to 8 weeks.
What to watch forSide effects
Common
Redness, swelling, itching, or a small bump where you injected
What to do Rotate sites and use a fresh syringe every time. If redness spreads or gets hot and painful, treat it as an infection (see below).
Mild nausea or stomach upset
What to do If it keeps happening, drop to 250 mcg (2.5 units) or stop.
Headache or brief lightheadedness
What to do Sit or lie down and drink water. If it is severe or keeps coming back, stop and talk to a doctor.
Stop and get help
Allergic reaction: hives, swelling of the face, lips, or throat, trouble breathing, or feeling faint. The FDA warns BPC-157 may trigger the immune system and may contain peptide impurities.
What to do Stop BPC-157 and call 911 (or your local emergency number) right away.
Infection at the injection site: redness that spreads, heat, pus, red streaks, or fever
What to do Stop injecting and see a doctor the same day.
Do not use if
- You are pregnant, trying to get pregnant, or breastfeeding: there is no safety data.
- You have cancer now or are being treated for it: BPC-157 grows new blood vessels in lab studies, and in theory that could help a tumor. This risk has not been tested.
- You are under 18.
- You compete in a drug-tested sport: WADA bans BPC-157 at all times, in and out of competition.
- You have a bleeding disorder or surgery coming up, unless your doctor agrees.
Sites and techniqueInjecting
Under the skin (subcutaneous)
- Belly, 2 inches from the navel
- Front of the thigh
- Near the injury (dashed ring: example)
Move each shot at least 1 inch (2-3 cm) from the last one and switch sides, so the same patch of skin is not used two days in a row.
Storage
- Keep it
- Keep the mixed vial in the fridge (2-8 °C / 36-46 °F), away from heat and light. Never leave it in a hot car.
- How long
- Use within 90 days of mixing. A mixed vial kept in the fridge holds its strength for 60-90 days, then slowly starts to lose potency. Wipe the rubber top with an alcohol swab before every draw.
Drawing your dose
Stop when the top edge of the black stopper reaches the 5 line.
Syringe: a 0.5 mL (50-unit) U-100 insulin syringe.
- With this mix, every 1 unit line on a U-100 insulin syringe holds 100 mcg. Draw to the 5-unit line for 500 mcg, or to 2.5 units for 250 mcg.
- Hold the syringe at eye level, flick out air bubbles, and push the plunger back to the exact line.
- Pinch a fold of skin, insert the needle at 45 to 90 degrees, push slowly, and wait a few seconds before pulling out.
- Use a new sterile syringe every time and never share one.
- Many people inject close to the sore area. This is a community habit; the peptide spreads through the body either way.
Stacks and interactionsPairs well with
-
TB-500 is sold as a form of thymosin beta-4, which binds actin (a cell's internal scaffolding) to help repair cells move, grow blood vessels, and reduce scarring: a different route to repair than BPC-157. The pair is the store's Wolverine stack. In one small knee review, 3 of 4 people given a knee injection of BPC-157 plus full thymosin beta-4 (not TB-500) improved. They have not been tested together.214
-
GHK-Cu raises collagen and elastin and supports skin repair, while BPC-157 sped wound healing in animals. They are paired in the store's Glow stack for skin repair; they have not been tested together.2215
-
KPV turned down the NF-kB inflammation switch in gut cells and reduced colitis (gut inflammation) in mice, while BPC-157 protected the gut lining in rats. They are paired in the store's KLOW stack; they have not been tested together.2314
Interactions
Blood thinners and anti-platelet drugs (warfarin, apixaban, clopidogrel, daily aspirin)
In rats, BPC-157 did not change standard clotting tests, yet it both reduced bleeding caused by blood thinners and prevented or broke up clots. A safety summary warns it could change how these drugs work, in either direction. This has not been studied in people.
What to do Ask the doctor who prescribes your blood thinner first, and never change its dose on your own. Report unusual bruising or bleeding, or signs of a clot such as a swollen, painful leg or sudden shortness of breath.
Nitrates (such as nitroglycerin) and erectile-dysfunction pills (sildenafil, tadalafil)
BPC-157 acts on the nitric oxide system, which these drugs also use. No human interaction has been reported, but it has not been studied.
What to do Ask your doctor first. Stand up slowly and stop if you feel dizzy or faint.
Cancer treatment, especially drugs that block blood-vessel growth (such as bevacizumab)
BPC-157 boosts the VEGFR2 blood-vessel signal in lab studies, which could in theory work against these drugs.
What to do Do not use BPC-157 during cancer treatment unless your oncologist approves.
Videos and sourcesKey references
Videos
-
BPC-157 & TB-500: The Truth About the Wolverine Stack
-
I Analyzed the Wolverine Stack Evidence—Here's What I Found
-
Benefits & Risks of Peptide Therapeutics (Huberman Lab)
Sources
- 1He et al., Front Pharmacol 2022 (pharmacokinetics in rats and dogs)Study
- 2Vasireddi et al., HSS Journal 2025 (systematic review, sports medicine)Review
- 3McGuire et al., Curr Rev Musculoskelet Med 2025 (Regeneration or Risk? review)Review
- 4Lee & Padgett, Altern Ther Health Med 2021 (knee injection, 16 patients)Study
- 5Lee, Walker & Ayadi, Altern Ther Health Med 2024 (interstitial cystitis pilot)Study
- 6Lee & Burgess, Altern Ther Health Med 2025 (IV safety pilot)Study
- 7FDA: Certain bulk drug substances for compounding that may present significant safety risks (BPC-157)Reference
- 8Staresinic et al., J Orthop Res 2003 (rat Achilles tendon)Study
- 9Staresinic et al., J Orthop Res 2006 (rat quadriceps muscle)Study
- 10Cerovecki et al., J Orthop Res 2010 (rat knee ligament)Study
- 11Chang et al., J Appl Physiol 2011 (tendon cell migration)Study
- 12Chang et al., Molecules 2014 (growth hormone receptor in tendon cells)Study
- 13Hsieh et al., J Mol Med 2017 (VEGFR2 and new blood vessels)Study
- 14Sikiric et al., Curr Pharm Des 2011 (gastrointestinal review)Review
- 15Seiwerth et al., Front Pharmacol 2021 (wound healing review)Review
- 16FDA Guidance 2005: Estimating the Maximum Safe Starting Dose (animal-to-human conversion)Reference
- 17German Sport University Cologne: WADA class S0 (non-approved substances), names BPC-157Reference
- 18Peptide Protocol Wiki: BPC-157 community protocols (150 reports)Community
- 19Peptide Protocol Wiki: BPC-157 side effectsCommunity
- 20Jay Campbell: BPC-157 dosage guidePractitioner
- 21Goldstein et al., Expert Opin Biol Ther 2012 (thymosin beta-4 review)Review
- 22Pickart & Margolina, Int J Mol Sci 2018 (GHK-Cu review)Review
- 23Dalmasso et al., Gastroenterology 2008 (KPV in mouse colitis)Study
Where people discuss it
The FDA and Big PharmaWhat “not FDA-approved” really means
Some peptides, like semaglutide (Ozempic and Wegovy), are FDA-approved medicines. Most of the peptides people research are not. That label sounds like the FDA tested something and turned it down. Usually it means something else: nobody has paid for the studies the FDA needs to see. Here is why.
The FDA doesn’t test drugs. Companies do.
The FDA does not run its own drug tests. A company that wants to sell a new medicine has to test it first, and pay for it. It studies the drug in animals, then in people: first 20 to 100 volunteers, then a few hundred, then up to 3,000. Then it sends all the results to the FDA. FDA scientists review them and decide whether the benefits outweigh the risks.
So approval always starts with a company asking for it. If no company applies, the FDA has nothing to review, however promising the research looks.
Those studies cost about a billion dollars
A study in the medical journal JAMA estimated that bringing one new drug to market costs a typical company about $1.1 billion. That figure includes the money spent on drug ideas that failed along the way, because many drugs that start human testing never make it.
A patent is how a company earns that money back
A patent is a right the government gives an inventor. For up to 20 years from the day the inventor applies, nobody else may make or sell the invention without permission.
For a drug company, that right is what makes the billion-dollar bet worth it. While the patent lasts, the company is the only seller, so it can charge enough to pay back the studies and the failures. When the patent runs out, other companies can sell cheap copies, called generics, and the price drops.
The FDA adds a shorter shield of its own. For 5 years after a brand-new drug is approved, no copycat version can apply for approval. That helps, but it is much shorter than a patent can last.
Why most peptides can’t be patented
To get a patent, an invention has to be new, and it has to be something people made, not something found in nature. Most popular peptides fail one test or both.
They come from nature. Many are copies or small pieces of molecules your body already makes. KPV is a 3-building-block piece of the hormone that tans your skin. BPC-157 is copied from a protein in stomach juice. In 2013 the US Supreme Court ruled that something that exists in nature, like a human gene, cannot be patented just because someone found it and pulled it out.
They aren’t new anymore. Many were first described in research papers decades ago. Scientists were already testing KPV in the 1980s. Once something has been published, it no longer counts as new, so nobody can patent it now, and any patents from back then have long since run out.
Without a patent, a company that paid for the studies would soon face rivals selling the same peptide without having paid for any research. Few companies will spend a billion dollars on a product anyone can copy. So nobody goes first, and the large human studies never happen.
The workaround: change the molecule
Drug companies do make peptide medicines, but they change the peptide first. A changed molecule is a new invention, so it can be patented. Semaglutide is a lab-made version of GLP-1, a gut hormone your body releases after meals, changed so one shot lasts a week. Tesamorelin (Egrifta) is the body’s own growth-hormone signal with a small fatty chain added. Both went through the full studies, and both are FDA-approved.
The natural versions, and the many peptides nobody has changed and patented, stay where they are: studied in labs and animals, used by the biohacking community, and never put through large human trials.
What this means for you
When a peptide is “not FDA-approved,” it usually means no company has paid for the large human studies. It does not mean the FDA tested it and found it harmful.
It also does not mean it is proven safe or proven to work. Without those studies, nobody knows the best dose for sure, or what rare or long-term side effects it may have. And the FDA does not check research peptides for purity or strength the way it checks approved medicines. That is why this page labels every finding by the kind of study behind it, and lists who should not use it.
Sources for this section
- 1FDA: How drugs are developed and approved (the FDA does not test drugs; companies submit the evidence)
- 2FDA: The drug development process, step 3: clinical research (study sizes for each phase)
- 3Wouters, McKee & Luyten, JAMA 2020, corrected 2022: median cost to bring a new drug to market, $1.14 billion
- 4US patent law, 35 U.S.C. § 154: a patent lasts 20 years from the filing date
- 5FDA: Frequently asked questions on patents and exclusivity (5-year new chemical entity exclusivity)
- 6US Supreme Court, Association for Molecular Pathology v. Myriad Genetics (2013): naturally occurring genes cannot be patented